Amber Denham

News
Shorter Duration of Adjuvant Therapy Does Not Compromise Efficacy in Colon Cancer: ACHIEVE Trial
05/19/2022
Study findings show that shortening adjuvant FOLFOX or CAPOX therapy from 6 to 3 months did not compromise efficacy among Asian patients with curatively resected colon cancer.
Study findings show that shortening adjuvant FOLFOX or CAPOX therapy from 6 to 3 months did not compromise efficacy among Asian patients with curatively resected colon cancer.
Study findings show that...
05/19/2022
Oncology
News
Lisocabtagene Maraleucel Demonstrates Efficacy, Manageable Safety Among Patients With R/R CLL/SLL
11/20/2023
Phase 1/2 trial results demonstrated that lisocabtagene maraleucel treatment induced complete response or remission, including with incomplete marrow recovery, among patients with R/R chronic lymphocytic leukemia or small lymphocytic lymphoma.
Phase 1/2 trial results demonstrated that lisocabtagene maraleucel treatment induced complete response or remission, including with incomplete marrow recovery, among patients with R/R chronic lymphocytic leukemia or small lymphocytic lymphoma.
Phase 1/2 trial results...
11/20/2023
Oncology
News
Efficacy of Azacitidine Among Treatment-Naive Patients With Higher-Risk Myelodysplastic Syndromes
01/31/2024
Azacitidine demonstrated low complete remission rates and low median overall survival as a frontline therapy for patients with high-risk myelodysplastic syndromes, according to a retrospective study.
Azacitidine demonstrated low complete remission rates and low median overall survival as a frontline therapy for patients with high-risk myelodysplastic syndromes, according to a retrospective study.
Azacitidine demonstrated low...
01/31/2024
Oncology
News
Pembrolizumab With Chemotherapy in Advanced or Recurrent Endometrial Cancer
07/24/2023
The combination of pembrolizumab with standard chemotherapy resulted in significantly longer progression-free survival among patients with advanced or recurrent endometrial cancer, compared with chemotherapy alone.
The combination of pembrolizumab with standard chemotherapy resulted in significantly longer progression-free survival among patients with advanced or recurrent endometrial cancer, compared with chemotherapy alone.
The combination of pembrolizumab...
07/24/2023
Oncology
News
Tisagenlecleucel Shows Comparable Efficacy, Superior Safety to Axicabtagene Ciloleucel Among Patients With R/R FL
01/22/2024
Recent study results suggested tisagenlecleucel was associated with similar efficacy and improved safety outcomes compared with axicabtagene ciloleucel treatment among patients with relapsed/refractory follicular lymphoma.
Recent study results suggested tisagenlecleucel was associated with similar efficacy and improved safety outcomes compared with axicabtagene ciloleucel treatment among patients with relapsed/refractory follicular lymphoma.
Recent study results suggested...
01/22/2024
Oncology
Conference Coverage
Financial Impact of Switching From Abiraterone to Generic Therapeutics for Patients With Prostate Cancer in the Oncology Care Model
06/03/2022
Therapeutic interchange from brand name to generic abiraterone in The US Oncology Network generated significant savings for the Oncology Care Model, according to a study presented at the 2022 ASCO Annual Meeting.
Therapeutic interchange from brand name to generic abiraterone in The US Oncology Network generated significant savings for the Oncology Care Model, according to a study presented at the 2022 ASCO Annual Meeting.
Therapeutic interchange from...
06/03/2022
Journal of Clinical Pathways
News
Momelotinib Yields Substantial Symptom Benefits Among Patients With Myelofibrosis
11/08/2023
Patient-reported outcomes from the phase 3 MOMENTUM trial demonstrated that momelotinib provided rapid and durable response benefits among anemic and symptomatic patients with myelofibrosis (MF). 
Patient-reported outcomes from the phase 3 MOMENTUM trial demonstrated that momelotinib provided rapid and durable response benefits among anemic and symptomatic patients with myelofibrosis (MF). 
Patient-reported outcomes from...
11/08/2023
Oncology
News
Venetoclax-Obinutuzumab Demonstrates Durable, Safe Responses for Patients With R/R CLL/SLL
02/05/2024
Venetoclax-obinutuzumab achieved frequent, durable, and safe responses among patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia, according to a retrospective, real-world study.
Venetoclax-obinutuzumab achieved frequent, durable, and safe responses among patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia, according to a retrospective, real-world study.
Venetoclax-obinutuzumab achieved...
02/05/2024
Oncology
Conference Coverage
Sintilimab Added to Chemoradiotherapy Improved Event-Free Survival in High-Risk Nasopharyngeal Carcinoma
07/18/2023
The addition of sintilimab to standard induction chemotherapy and concurrent chemoradiotherapy resulted in improved event-free survival in high-risk LANPC.
The addition of sintilimab to standard induction chemotherapy and concurrent chemoradiotherapy resulted in improved event-free survival in high-risk LANPC.
The addition of sintilimab to...
07/18/2023
Oncology
News
Rituximab Plus Lenalidomide Treatment Shows Promise for Older Patients with DLBCL
01/11/2024
The combination of rituximab and lenalidomide demonstrated feasibility and moderate activity as frontline therapy for older patients with diffuse large B-cell lymphoma, according to a recent study.
The combination of rituximab and lenalidomide demonstrated feasibility and moderate activity as frontline therapy for older patients with diffuse large B-cell lymphoma, according to a recent study.
The combination of rituximab and...
01/11/2024
Oncology

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use